发明公开
EP2314316A1 Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
审中-公开
人类中性抗OPGLAntikörperals selektive OPGL途径抑制剂
- 专利标题： Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
- 专利标题（中）： 人类中性抗OPGLAntikörperals selektive OPGL途径抑制剂
-
申请号： EP10010381.1申请日： 2003-04-07
-
公开(公告)号： EP2314316A1公开(公告)日： 2011-04-27
- 发明人: Boyle, William J. , Medlock, Eugene , Sullivan, John K. , Elliott, Robin L. , Martin, Francis H. , Huang, Haichun
- 申请人： Amgen, Inc , Medarex, Inc.
- 申请人地址： One Amgen Center Drive Thousand Oaks, CA 91320-1799 US
- 专利权人： Amgen, Inc,Medarex, Inc.
- 当前专利权人： Amgen, Inc,Medarex, Inc.
- 当前专利权人地址： One Amgen Center Drive Thousand Oaks, CA 91320-1799 US
- 代理机构： Grünecker, Kinkeldey, Stockmair & Schwanhäusser Anwaltssozietät
- 优先权： US370407P 20020405
- 主分类号： A61K39/395
- IPC分类号： A61K39/395 ; C12N15/00 ; C07K16/00
摘要：
Monoclonal antibodies and hybridomas producing them that interact with osteoprotegerin ligand (OPGL) are provided. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are also provided. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are further provided.
信息查询
